All News

pills-384846_640%20%281%29.jpg

The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis

Richard Conway, MBBChBAO, PhD

Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.

Read Article
gout.podagra.jpg

Pegloticase in Severe Refractory Gout

Olga Petryna, MD

Listen as Dr. Petryna reviews abstracts #0683 (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate) and #0677 (A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study) from the 2020 ACR meeting. 

Read Article
Lknee.OA_.jpg

What’s new in knee osteoarthritis that matters?

Janet Pope, MD, MPH, FRCPC

Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.

Read Article
podcast logo

RheumNow Podcast – ACR 2020 Epilogue (11.20.20)

Jack Cush, MD

Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.

Read Article
kneepain3.jpg (keep)

Warfarin and End-Stage Osteoarthritis

David Liew, FRACP

Dr. David Liew discusses abstract #0934 - "Warfarin Use and Risk of Knee and Hip Replacements" - presented at the 2020 ACR annual meeting.

Read Article
#BestACR20Tweets RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets "RT @DrMiniDey : RITAZAREM trial long-term f/u -RTX vs AZA after RTX-induced remission in ANCA -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 https://t.co/cKV7qM77og

Links:

Dr. John Cush RheumNow ( View Tweet)

New video! Risk of HCQ Retinopathy: Dr. Kathryn Dao ( @KDAO2011) #ACR20 https://t.co/7BCVvMOm0T https://t.co/DOW91SSi2u

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate. https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y

Links:

Dr. John Cush RheumNow ( View Tweet)
What is the SEAMless transition from combination Etanercept to Methotrexate? with Dr. Jonathan Kay #ACR20 https://t.co/58raeaE8Mr https://t.co/FUIidcoy4I

Links:

Dr. John Cush RheumNow ( View Tweet)
Check out our article titled: FAST, FREED, CARES, & CONFIRMS: A Run-Down on the Black-Box Blues of Febuxostat by Dr. Meral K. El Ramahi ( @MeralElRamahiMD). #ACR20 https://t.co/dKhotXONGP https://t.co/KfsFFX7z0D

Links:

Dr. John Cush RheumNow ( View Tweet)
Improving Drug Adherence in RA: Dr Janet Pope ( @Janetbirdope) Reviews abstract #799 presented at #ACR20. https://t.co/ONCJmCOdzC https://t.co/ornpQiopTS

Links:

Dr. John Cush RheumNow ( View Tweet)
SEAM-RA Trial: Dr. Jeff Curtis ( @RADoctor) discusses abstract # 0939 that looked at whether RA patients at or close to remission should continue taking their combination therapy, as presented at #ACR20 https://t.co/2yMyj4BKs1 https://t.co/2gqJM4EKpG

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. David Liew ( @drdavidliew) reviews abstracts #0431 on HCQ and QTc Prolongation as presented at #ACR20. https://t.co/vbqf7UNzVY https://t.co/qBCqFqYQCo

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @KDAO2011 : FDA updates 6/16/20 canakinumab for AOSD 5/29/20 ixekizumab for nr-AxSpa 80 mg q4wks 3/9/20 nintedanib for progressive ILD 1/29/20 and 6/16/20 secukinumab nr-axSpa 150 mg q4wks, AS 300 mg SQ q4weeks 1/17/20 belimumab label for black pts removed

Dr. John Cush RheumNow ( View Tweet)

Moderna mRNA-1273 vaccine, developed for COVID-19, yielded 94.5% efficacy in early results of the phase 3 COVE trial. 90 who were COVID-19 pos were in a placebo group and that 5 patients were in the mRNA-1273 vaccine group. https://t.co/9245wj3kph

Links:

Dr. John Cush RheumNow ( View Tweet)

Mortality in Low Dose Prednisone by Dr. Eric Dein ( @ejdein1). #ACR20 https://t.co/y6dL9V6iDC https://t.co/e7119ymgiq

Links:

Dr. John Cush RheumNow ( View Tweet)
Methotrexate Induced Liver Fibrosis: Dr. Sheila Reyes ( @RHEUMarampa) discusses abstract #0205 presented Friday at the #ACR20 annual meeting. https://t.co/P80WIGXOPg https://t.co/xEAuxSqIQv

Links:

Dr. John Cush RheumNow ( View Tweet)
Does Hydroxychloroquine Hurt the Heart? Dr. Jonathan Kay examines an #ACR29 study (abstract #0431) looking at whether hydroxychloroquine use has injured patients' hearts. https://t.co/vwS5AwCmZ9 https://t.co/H47NA4MxTg

Links:

Dr. John Cush RheumNow ( View Tweet)
Racial Disparities - Stroke, Heart Attacks Risks Higher in SLE: Dr. Kathryn Dao ( @KDAO2011) discusses abstract #0433 presented Friday at #ACR20 annual meeting. https://t.co/Jx8hiPcNKA https://t.co/MvUj41KiuQ

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×